Market Closed -
OTC Markets
01:29:59 11/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.32
USD
|
+6.24%
|
|
+4.23%
|
-92.84%
|
Fiscal Period: December |
2021
|
2022
|
---|
Capitalization
1 |
660.6
|
177.7
|
Enterprise Value (EV)
1 |
282.2
|
-120.3
|
P/E ratio
|
-1.08
x
|
-1.6
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
EV / Revenue
|
-
|
-
|
EV / EBITDA
|
-14,46,726
x
|
9,67,645
x
|
EV / FCF
|
-28,29,938
x
|
26,01,502
x
|
FCF Yield
|
-0%
|
0%
|
Price to Book
|
1.87
x
|
0.68
x
|
Nbr of stocks (in thousands)
|
1,07,239
|
1,08,354
|
Reference price
2 |
6.160
|
1.640
|
Announcement Date
|
31/03/22
|
28/03/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-134.8
|
-195
|
-124.3
|
EBIT
1 |
-24.34
|
-134.9
|
-195.6
|
-125.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-24.33
|
-139.6
|
-195.8
|
-110.6
|
Net income
1 |
-24.33
|
-139.6
|
-196.3
|
-110.3
|
Net margin
|
-
|
-
|
-
|
-
|
EPS
2 |
-11.98
|
-11.58
|
-5.707
|
-1.022
|
Free Cash Flow
|
-
|
-102.8
|
-99.71
|
-46.25
|
FCF margin
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/08/21
|
09/08/21
|
31/03/22
|
28/03/23
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-13.27
|
-21.79
|
-28.15
|
-43
|
-23.45
|
-28.93
|
-25.64
|
-24.71
|
-25.98
|
EBIT
1 |
-13.54
|
-22.04
|
-60.5
|
-43.14
|
-24.55
|
-29.24
|
-25.97
|
-25.04
|
-26.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.51
|
-22.23
|
-60.59
|
-42.39
|
-21.89
|
-18.63
|
-23.61
|
-21.42
|
-23.45
|
Net income
1 |
-13.11
|
-21.2
|
-61.56
|
-42.39
|
-21.9
|
-18.28
|
-24.04
|
-21.62
|
-24.04
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6300
|
-0.2800
|
-3.010
|
-0.3900
|
-0.2000
|
-0.1700
|
-0.2200
|
-0.2000
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/12/21
|
30/03/22
|
12/05/22
|
11/08/22
|
10/11/22
|
27/03/23
|
11/05/23
|
14/08/23
|
13/11/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
Net Cash position
1 |
42.8
|
252
|
378
|
298
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-103
|
-99.7
|
-46.3
|
ROE (net income / shareholders' equity)
|
-
|
-95.7%
|
-61.4%
|
-32.4%
|
ROA (Net income/ Total Assets)
|
-
|
-52.2%
|
-34.6%
|
-21%
|
Assets
1 |
-
|
267.6
|
566.6
|
525.3
|
Book Value Per Share
2 |
-3.250
|
-6.490
|
3.300
|
2.430
|
Cash Flow per Share
2 |
8.890
|
12.40
|
2.130
|
0.7400
|
Capex
|
-
|
0.89
|
0.95
|
1.85
|
Capex / Sales
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/08/21
|
09/08/21
|
31/03/22
|
28/03/23
|
|
1st Jan change
|
Capi.
|
---|
| -92.84% | 34.61M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|